Table of Contents
21 relations: Androgen backdoor pathway, Cl-4AS-1, Dihydrotestosterone, Dutasteride, Feminizing hormone therapy, Finasteride, Izonsteride, List of human protein-coding genes 4, List of OMIM disorder codes, MK-386, MK-434, Pharmacodynamics of progesterone, SRD5A1, Steroidogenic enzyme, TFM-4AS-1, Turosteride, 11-Ketoandrosterone, 5α-Pregnan-17α-ol-3,20-dione, 5α-Reductase, 5α-Reductase 2 deficiency, 5α-Reductase inhibitor.
Androgen backdoor pathway
The androgen backdoor pathway is responsible for the synthesis of physiologically relevant androgens.
See SRD5A2 and Androgen backdoor pathway
Cl-4AS-1
Cl-4AS-1 is a dual anabolic–androgenic steroid (AAS) and 5α-reductase inhibitor.
Dihydrotestosterone
Dihydrotestosterone (DHT, 5α-dihydrotestosterone, 5α-DHT, androstanolone or stanolone) is an endogenous androgen sex steroid and hormone primarily involved in the growth and repair of the prostate and the penis, as well as the production of sebum and body hair composition.
See SRD5A2 and Dihydrotestosterone
Dutasteride
Dutasteride, sold under the brand name Avodart among others, is a medication primarily used to treat the symptoms of a benign prostatic hyperplasia (BPH), an enlarged prostate not associated with cancer.
Feminizing hormone therapy
Feminizing hormone therapy, also known as transfeminine hormone therapy, is hormone therapy and sex reassignment therapy to change the secondary sex characteristics of transgender people from masculine or androgynous to feminine.
See SRD5A2 and Feminizing hormone therapy
Finasteride
Finasteride, sold under the brand names Proscar and Propecia among others, is a medication used to treat pattern hair loss and benign prostatic hyperplasia (BPH) in men.
Izonsteride
Izonsteride (developmental code name LY-320,236) is a selective inhibitor of the 5α-reductase, with dual effects on both the type I and type II isoforms of the enzyme.
List of human protein-coding genes 4
Human protein-coding genes 4.
See SRD5A2 and List of human protein-coding genes 4
List of OMIM disorder codes
This is a list of disorder codes in the Online Mendelian Inheritance in Man (OMIM) database.
See SRD5A2 and List of OMIM disorder codes
MK-386
MK-386, also known as 4,7β-dimethyl-4-aza-5α-cholestan-3-one, is a synthetic, steroidal 5α-reductase inhibitor which was first reported in 1994 and was never marketed.
MK-434
MK-434 is a 5α-reductase inhibitor which was under development in the 1990s by Merck & Co for the treatment of a variety of androgen-dependent conditions including benign prostatic hyperplasia, prostate cancer, pattern hair loss, excessive hair growth, acne, and seborrhea but was never marketed.
Pharmacodynamics of progesterone
The pharmacology of progesterone, a progestogen medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration.
See SRD5A2 and Pharmacodynamics of progesterone
SRD5A1
3-Oxo-5α-steroid 4-dehydrogenase 1 is an enzyme that in humans is encoded by the SRD5A1 gene.
Steroidogenic enzyme
Steroidogenic enzymes are enzymes that are involved in steroidogenesis and steroid biosynthesis.
See SRD5A2 and Steroidogenic enzyme
TFM-4AS-1
TFM-4AS-1 is a dual selective androgen receptor modulator (SARM) and 5α-reductase inhibitor.
Turosteride
Turosteride (FCE-26,073) is a selective inhibitor of the enzyme 5α-reductase which was under investigation by GlaxoSmithKline for the treatment of benign prostatic hyperplasia (BPH), but was never marketed.
11-Ketoandrosterone
11-Ketoandrosterone is an endogenous steroid.
See SRD5A2 and 11-Ketoandrosterone
5α-Pregnan-17α-ol-3,20-dione
5α-Pregnan-17α-ol-3,20-dione, also known as 17α-hydroxy-dihydroprogesterone (17‐OH-DHP) is an endogenous steroid, a metabolite of 17α-hydroxyprogesterone.
See SRD5A2 and 5α-Pregnan-17α-ol-3,20-dione
5α-Reductase
5α-Reductases, also known as 3-oxo-5α-steroid 4-dehydrogenases, are enzymes involved in steroid metabolism.
5α-Reductase 2 deficiency
5α-Reductase 2 deficiency (5αR2D) is an autosomal recessive condition caused by a mutation in SRD5A2, a gene encoding the enzyme 5α-reductase type 2 (5αR2).
See SRD5A2 and 5α-Reductase 2 deficiency
5α-Reductase inhibitor
5α-Reductase inhibitors (5-ARIs), also known as dihydrotestosterone (DHT) blockers, are a class of medications with antiandrogenic effects which are used primarily in the treatment of enlarged prostate and scalp hair loss.
See SRD5A2 and 5α-Reductase inhibitor
References
Also known as 5α Reductase 2, 5α Reductase II, 5α Reductase type 2, 5α Reductase type II, 5α-Reductase 2, 5α-Reductase II, 5α-Reductase type 2, 5α-Reductase type II, SRD5A2 (gene).